المؤلفون: Anna Soria, Mariona Calvo, Meritxell Casas, Zara Vidales, Sergio Muñoz-Martínez, Victor Sapena, Marc Puigvehi, Lidia Canillas, Raquel Guardeño, Adolfo Gallego, Beatriz Mínguez, Diana Horta, Ariadna Clos, Silvia Montoliu, Mercè Roget, Maria Reig, Mercedes Vergara

المصدر: Frontiers in Oncology, Vol 12 (2022)

مصطلحات موضوعية: sorafenib, elderly patients, hepatocellular carcinoma, overall survival, safety, outcome, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.829483/full; https://doaj.org/toc/2234-943X

URL الوصول: https://doaj.org/article/ee56ec9457554833bfaf62de8c746951

المؤلفون: Berta Laquente, Teresa Macarulla, Cristina Bugés, Marta Martín, Carlos García, Carles Pericay, Sandra Merino, Laura Visa, Teresa Martín, Manuela Pedraza, Beatriz Carnero, Raquel Guardeño, Helena Verdaguer, Alejandro Mut, David Vilanova, Adelaida García

المصدر: BMC Palliative Care, Vol 19, Iss 1, Pp 1-11 (2020)

مصطلحات موضوعية: Pancreatic Cancer, Health-related quality of life, Cancer chemotherapy, Performance status, EORTC QLQ-C30, Special situations and conditions, RC952-1245

وصف الملف: electronic resource

Relation: http://link.springer.com/article/10.1186/s12904-020-00610-4; https://doaj.org/toc/1472-684X

URL الوصول: https://doaj.org/article/5824c2ac1526441d88539ddec53997ec

المؤلفون: Manish A. Shah, Anghel Adrian Udrea, Igor Bondarenko, Was Mansoor, Raquel Guardeño Sánchez, Tomasz Sarosiek, Silvia Bozzarelli, Michael Schenker, Carlos Gomez-Martin, Carys Morgan, Mustafa Özgüroğlu, Joanna Pikiel, Haralabos P. Kalofonos, Elzbieta Wojcik, Tomas Buchler, Daniel Swinson, Irfan Cicin, Mano Joseph, Ihor Vynnychenko, Alexander Valerievich Luft, Peter C. Enzinger, Tomas Salek, Christos Papandreou, Christophe Tournigand, Evaristo Maiello, Ran Wei, David Ferry, Ling Gao, Joana M. Oliveira, Jaffer A. Ajani

المصدر: Cancers, Vol 14, Iss 5, p 1168 (2022)

مصطلحات موضوعية: angiogenesis, gastric adenocarcinoma, ramucirumab, vascular endothelial growth factor receptor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.mdpi.com/2072-6694/14/5/1168; https://doaj.org/toc/2072-6694

URL الوصول: https://doaj.org/article/0553a5845acd48c2aeae5976fde4d9de

المؤلفون: Wainberg, Zev A.^{Aff1, IDs1012002401466w_cor1}, Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian A., Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Zahlten-Kümeli, Anita, Taylor, Kate, Enzinger, Peter C.

المصدر: Gastric Cancer. 27(3):558-570

المؤلفون: Wainberg, Zev A ^*, Enzinger, Peter C, Kang, Yoon-Koo, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Borg, Christophe, Hitre, Erika, Udrea, Adrian A, Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Collins, Helen, Mitra, Siddhartha, Yang, Yingsi, Catenacci, Daniel V T, Lee, Keun-Wook

المصدر: In The Lancet Oncology November 2022 23(11):1430-1440

المؤلفون: Borg, Christophe, Wainberg, Zev A, Hitre, Erika, Teixeira, Alexandra, Enzinger, Peter C, Kang, Yoon-Koo, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, HACI MEHMET, Lee, Keun-Wook, Catenacci, Daniel V T, Yang, Yingsi, Mitra, Siddhartha, Collins, Helen, Sanchez, Raquel Guardeño, Cardellino, Giovanni Gerardo, Udrea, Adrian A

المساهمون: TÜRK, HACI MEHMET

المصدر: The Lancet. Oncology. 23(11)

مصطلحات موضوعية: Male, a randomised, double-blind, placebo-controlled, phase 2 study.-, The Lancet. Oncology, 2022 [Wainberg Z. A. , Enzinger P. C. , Kang Y., Qin S., Yamaguchi K., Kim I., Saeed A., Oh S. C. , Li J., Turk H. M. , et al., -Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT)], Leucovorin, Middle Aged, Adenocarcinoma, Oxaliplatin, Oncology, Double-Blind Method, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Esophagogastric Junction, Fluorouracil, Receptor, Fibroblast Growth Factor, Type 2

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f4ff5ea59bc97884fc39ccafaad9049
https://pubmed.ncbi.nlm.nih.gov/36244398

المؤلفون: Adelaida García-Velasco, Lluís Zacarías-Pons, Helena Teixidor, Marc Valeros, Raquel Liñan, M. Carmen Carmona-Garcia, Montse Puigdemont, Walter Carbajal, Raquel Guardeño, Núria Malats, Eric D

المصدر: MDPI, IJERPH. 17(24):1-22

الإتاحة: https://ideas.repec.org/a/gam/jijerp/v17y2020i24p9538-d465214.html

المؤلفون: Zev A. Wainberg, Keun-Wook Lee, Inho Kim, Anwaar Saeed, Giovanni Gerardo Cardellino, Alexandra Carolina Teixeira, Daniel V.T. Catenacci, Raquel Guardeño, Christophe Borg, Siddhartha Mitra, Erika Hitre, Jin Li, Anghel Adrian Udrea, Yoon-Koo Kang, Kensei Yamaguchi, Yingsi Yang, Sang Cheul Oh, Shukui Qin, Peter C. Enzinger, Haci Mehmet Turk

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, business.industry, medicine.drug_class, Phases of clinical research, Gastroesophageal Junction Adenocarcinoma, Placebo, Monoclonal antibody, Gastroenterology, Double blind, Oncology, A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 [Catenacci D. V. T. , Kang Y., Saeed A., Yamaguchi K., Qin S., Lee K., Kim I., Oh S. C. , Li J., Turk H. M. , et al., -FIGHT], Internal medicine, Fibroblast Growth Factor Receptor 2b, Medicine, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84cd51b695b646eaa8b082749dbaa24
http://hdl.handle.net/20.500.12645/29666

المؤلفون: Núria Malats, Walter Carbajal, Adelaida Garcia-Velasco, Rafael Marcos-Gragera, Lluís Zacarías-Pons, Raquel Liñan, Montse Puigdemont, M Carmen Carmona-Garcia, Eric J. Duell, Helena Teixidor, Raquel Guardeño, Marc Valeros

المصدر: Repisalud
Instituto de Salud Carlos III (ISCIII)
International Journal of Environmental Research and Public Health
Volume 17
Issue 24
International Journal of Environmental Research and Public Health, Vol 17, Iss 9538, p 9538 (2020)

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Adolescent, Health, Toxicology and Mutagenesis, Population, pancreatic cancer, lcsh:Medicine, Article, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, Medicine, Humans, 030212 general & internal medicine, Registries, education, Survival rate, Aged, education.field_of_study, Relative survival, business.industry, Incidence (epidemiology), Incidence, lcsh:R, Public Health, Environmental and Occupational Health, relative survival, Middle Aged, pancreatic neuroendocrine tumours, Confidence interval, Cancer registry, Pancreatic Neoplasms, Survival Rate, Spain, 030220 oncology & carcinogenesis, Population Surveillance, Cohort, incidence, Female, business, International Classification of Diseases for Oncology

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::622b7772db4a04a84b7ba41960fa5af8
http://hdl.handle.net/20.500.12105/13094

المؤلفون: Keun-Wook Lee, Zev A. Wainberg, Yingsi Yang, Shukui Qin, Helen Collins, Haci Mehmet Turk, Siddhartha Mitra, Giovanni Gerardo Cardellino, Alexandra Carolina Teixeira, Yoon-Koo Kang, Sang Cheul Oh, Daniel V.T. Catenacci, Kensei Yamaguchi, Raquel Guardeño, Jin Li, Peter C. Enzinger

المساهمون: TÜRK, HACI MEHMET

المصدر: Journal of Clinical Oncology. 39:160-160

مصطلحات موضوعية: Cancer Research, medicine.drug_class, business.industry, First line, Phases of clinical research, Gastroesophageal Junction Adenocarcinoma, Pharmacology, Placebo, Monoclonal antibody, Double blind, Wainberg Z. A. , Enzinger P. C. , Kang Y., Yamaguchi K., Qin Shukui Q. S. , Lee K., Oh S. C. , Li Jin L. J. , TÜRK H. M. , Teixeira A. C. , et al., -Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, business, 030215 immunology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dfff608f3c1c9cd07f54b7554dd6501
https://doi.org/10.1200/jco.2021.39.3_suppl.160